Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: Evidence for monocyte activation

Journal of Immunotherapy

Volumn 19, Issue 3, 1996, Pages 231-243

  Keever Taylor, C A ^a   Witt, P L ^a   Truitt, R L ^a   Ramanujam, S ^a   Borden, E C ^a   Ritch, P S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Advanced cancer; IL 6; Immunology; Monocytes; Phase I trial

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; MESSENGER RNA; NEOPTERIN; RECOMBINANT INTERLEUKIN 6; SIGOSIX; SYNTHETASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW CELL; CHILL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOPHENOTYPING; LEIOMYOSARCOMA; LEUKOCYTE COUNT; MALE; MELANOMA; MONOCYTE; NEUROTOXICITY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 0030018896     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199605000-00008     Document Type: Article

References (54)

1. Borden EC, Truitt RL, Keever CA. Role of IL-4, IL-6, and IL-12 in cancer therapy. In: Devita VT, Heilman S, Rosenberg SA, eds. Biologic therapy of cancer: principles and practice. Philadelphia: JB Lippincott, 1995:279-93.
2. Poupart P, Vendenabeele P, Cayphas S, et al. B cell growth modulating and differentiating activity of recombinant human 26 kd protein (BSF-2, Hull-N-p-2, HPGF). EMBO J 1987;6:1219-24.
3. Kawano M, Kirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-5.
4. Tosato G, Tanner J, Jones K, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 1990;64:3033-41.
5. Hirano T, Yasukawa K, Hara H, et al. Complementary DNA for novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-6.
6. Garman RD, Jacobs KA, Clark SC, Raulet DH. B-cellstimulatory factor 2 (β2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sei USA 1987;84:7629-33.
7. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988;141:1543-9.
8. Lotz M, Jirik F, Kabouridis P, et al. B-cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988;167:1253-8.
9. Luger TA, Krutmann J, Kimbauer R, et al. INF-β2/IL-6 augments the activity of human natural killer cells. J Immunol 1989;143:1206-9.
10. Borish L, Rosenbaum R, Albury L, Clark S. Activation of neutrophils by recombinant interleukin 6. Cell Immunol 1989;121:280-9.
11. Tsang K, Finch M, Primus F, Schlom J. Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells. Cancer Immunol Immunother 1991;34:9-16.
12. Mule JJ, McIntosh JK, Jablons DM, Rosenberg SA. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 1990;171:629-36.
13. Mule JJ, Custer MC, Travis WD, Rosenberg SA. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 1992;148:2622-9.
14. Eisenthal A, Kashtan H, Rabau M, Ramakrishna V, Chaitchik S, Skomick Y. Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells. Cancer Immunol Immunother 1993;36:101-7.
15. Lu L, Shen RN, Broxmeyer HE. In vivo effects of recombinant human interleukin 6, alone or in combination with local irradiation, on tumor growth in lewis lung carcinomabearing mice. Int J Cell Cloning 1991;9:551-60.
16. Weber J, Gunn H, Yang J, et al. Phase I studies of intravenous interleukin-6 in patients with advanced cancer. J Immunother 1994;15:292-302.
17. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al. AIDS Kaposi’s sarcoma derived cells produce and respond to interleukin 6. Proc Natl Acad Sei USA 1990;87:4068-72.
18. Weber J, Yang J, Topailian S, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993;11:499-506
19. Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe J, Stem PL. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother 1994;38:119-26.
20. van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994;84:1434-41.
21. Pettengell R, Luft T, de Wynter E, et al. Effects of interleukin-6 on mobilization of primitive haemopoietic cells into the circulation. Br J Haematol 1995;89:237-42.
22. Aronson FR, Sznol M, Mier J, et al. Interleukin-6: phase I trials of 1- and 120-hr intravenous infusions. Proc Annu Meet Am Soc Clin Oncol 1993;12:A952.
23. Olencki T, Budd G, Murthy S, et al. Immunoregulatory and hematopoietic effects of interleukin-6 (rhIL-6) in cancer patients. Proc Annu Meet Am Soc Clin Oncol 1993;12:A950.
24. Dunlop DJ, Campbell SM, McNair L, Holyoake T, Rampling R, Steward WP. Phase I/Ib study of glycosylated recombinant human interleukin-6 in patients receiving chemotherapy for advanced malignancy, glioma and ovarian carcinoma. Proc Annu Meet Am Assoc Cancer Res 1994;35: A1184.
25. Lestingi TM, Richards JM, Shulman K, Gale D, Karius D, Isaacs R, Levitt D. Pilot phase II study of recombinant human interleukin-6 (rhIL-6) and chemotherapy (CT) in metastatic melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 1994;13:A1346.
26. Bouffet E, Blay J, Combaret V, et al. Phase I study of subcutaneous recombinant IL6 in children with advanced solid tumors. Proc Annu Meet Am Soc Clin Oncol 1994;13:A1434.
27. Sznol M, Mier J, Dutcher JP, Sosman JA, Weiss GR, Isaacs R, Margolin KA. A phase II trial of a daily 1-hour intravenous infusion of interleukin-6 (rHuIL-6) for metastatic malignant melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 1994;13:A1348.
28. Weiss GR, Margolin KA, Sznol M, et al. A phase II trial of a 120-hr continuous intravenous (CIV) infusion of interleukin-6 (rHuIL-6) for metastatic renal cell carcinoma (RCC). Proc Annu Meet Am Soc Clin Oncol 1994;13:A779.
29. Novick D, Eshhar Z, Revel M, Mory Y. Monoclonal antibodies for affinity purification of IL-6/INFβ-2 and for neutralization of HGF activity. Hybridoma 1989;8:561-7.
30. Wittes RE, ed. Manual of oncologic therapeutics. Philadel-phia: Lippincott, 1989:627-32.
31. Pike BL, Robinson WA. Human bone marrow colony growth in agar-gel. J Cell Physiol 1970;76:77-84.
32. Mazur EM, Hoffman R, Chasis J, Marchesi S, Bruno E. Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. Blood 1981;57:277-86.
33. Witt PL, Spear GT, Helgeson DO, Lindstrom MJ, Smalley RV, Borden EC. Basal and interferon-induced 2',5'- oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages. J Interferon Res 1990; 10:393-402.
34. Koutouby R, Zucker C, Zucker K, et al. Molecular monitoring of the immunosuppressive effects of cyclosporin in renal transplant patients using a quantitative polymerase chain reaction. Hum Immunol 1993;36:227-34.
35. Miller RG. Simultaneous statistical inference. New York: Springer Verlag, 1981.
36. Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkman EM. Interleukin-6 associated anemia: determination of the underlying mechanism. Blood 1995;86:1288-91.
37. Nieken J, Mulder NH, Buter J, et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995;86:900-5.
38. Lanier LL, Le AM, Civin Cl, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-6.
39. Zola H, Flego L, Macardle PJ, Donohoe PJ, Ranford J, Robeton D. The CD45RO (p180, UCHL1) marker: complexity of expression in peripheral blood. Cell Immunol 1992; 145: 175-86.
40. Gauldie J, Geisterfer M, Richards C, Baumann H. IL-6 regulation of the hepatic acute phase response. In: Revel M, ed. IL-6: physiopathology and clinical potential. Serono symposia. New York: Raven Press, 1992:151-62.
41. Spinedi E, Hadid R, Daneva T, Gaillard RC. Cytokines stimulate the CRH but not the vasopressin neuronal system: evidence for a median eminence site of interleukin-6 action. Neuroendocrinology 1992;56:45-53.
42. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690-4.
43. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 1994;79:934-9.
44. Tominaga T, Fukata J, Naito Y, et al. Prostaglandin dependent in vitro stimulation of adrenocortical steroidogenesis by interleukins. Endocrinology 1991;128:526-31.
45. Davis S, Aldrich TH, Valenzuela DM, et al. The receptor for ciliary neurotrophic factor. Science 1991;253:59-63.
46. Imai T, Koike K, Kubo T, et al. Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood 1991;78:1969-74.
47. Damle NK, Mohagheghpour N, Hansen JA, Engleman EG. Alloantigen-specific cytotoxic and suppressor T lymphocytes are derived from phenotypically distinct precursors. J Immunol 1983;131:2296-300.
48. Baroja ML, Ceuppens JL, Damme JV, Billiau A. Cooperation between an anti-T cell (anti-CD28) monoclonal antibody and monocyte-produced IL-6 in the induction of T cell responsiveness to IL-2. J Immunol 1988;141:1502-7.
49. Katz A, Shulman L, Revel M, Feldman M, Eisenbach L. Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas. IntJ Cancer 1993;53:812-18.
50. Marcus SG, Perry-Lalley D, Mule JJ, Rosenberg SA, Yang JC. The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. J Immunother 1994;15:105-12.
51. Andreesen R, Osterholz J, Bodemann H, Bross K, Costabel U, Lohr G. Expression of transferrin receptors and intracellular ferritin during terminal differentiation of human monocytes. Blut 1984;49:195-202.
52. Huber C, Batchelor JR, Fuchs D, et al. Immune response associated production of neopterin: release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310-16.
53. Witt PL, Storer BE, Helgeson DO, Borden EC. Interferon induced proteins in clinical trials: 2',5'-oligoadenylate synthetase as a prototype: In: Kawade Y, Sobayashe S, eds. The biology of the interferon system, 1988. Tokyo: Dodansha Scientific Press, 1989:195-200.
54. Schoester M, Heinrich PC, Graeve L. Regulation of interleukin-6 receptor expression by interleukin-6 in human monocytes-a re-examination. FEBS Lett 1994;345:131-4.